<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33109706</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>171</EndPage><MedlinePgn>165-171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-323271</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This was a post hoc analysis of the Edaravone Phase III Study MCI186-19 ('Study 19') to examine the utility of clinical staging systems as end points in clinical trials in amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS">Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised item scores from Study 19 were retrospectively mapped to King's stage and Milano-Torino staging (MiToS) stage. We assessed the percentage of patients who experienced progression in King's and MiToS stages during Study 19. We also assessed disease progression in subgroups of patients according to baseline King's stage.</AbstractText><AbstractText Label="RESULTS">During double-blind treatment, the percentage of patients who experienced a progression in King's stage was lower for edaravone (42.0%, 95% CI 30.4% to 53.6%) than placebo (55.9%, 95% CI 44.1% to 67.6%). The most pronounced effect was noted among patients who were in stage 1 and was maintained throughout open-label treatment. An analysis of a &#x2265;2-stage progression in MiToS stage showed no difference between treatment arms during double-blind treatment, but during the open-label period, more rapid progression was noted among patients in the placebo-edaravone arm than among those in the edaravone-edaravone arm (log-rank test, p&lt;0.001).</AbstractText><AbstractText Label="CONCLUSIONS">The King's and MiToS staging systems provided utility in assessing clinical progression in Edaravone Study 19. These findings may support the use of staging systems as end points in ALS clinical trials and to understand the timing of benefit as measured by these scales.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neurosciences, ALS Centre, University of Turin and Azienda Ospedaliero Universitaria Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc, Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oster</LastName><ForeName>Gerry</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Policy Analysis Inc, Brookline, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bornheimer</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Policy Analysis Inc, Brookline, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agnese</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc, Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc, Jersey City, New Jersey, USA stephen_apple@mt-pharma-us.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):117</RefSource><PMID Version="1">33109705</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: AA-C serves as a consultant for Chronos Therapeutics, OrionPharma, GSK, Novartis, Lilly, Biogen Idec, AB Science, Cytokinetics Inc, MTPA, Mitsubishi Tanabe Pharma Europe and Treeway. AC serves as a consultant for Biogen and MTPA and receives research support from the Italian Ministry of Health and Italian Ministry of Education, University and Research. GO and RB served as consultants to MTPA, in their capacities as employees at Policy Analysis, which provides consulting and contract research services to biopharma companies. CM and WA are former employees of MTPA. SA is an employee of MTPA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33109706</ArticleId><ArticleId IdType="pmc">PMC7841496</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-323271</ArticleId><ArticleId IdType="pii">jnnp-2020-323271</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goetz CG, Poewe W, Rascol O, et al. . Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020&#x2013;8. 10.1002/mds.20213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20213</ArticleId><ArticleId IdType="pubmed">15372591</ArticleId></ArticleIdList></Reference><Reference><Citation>Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease The unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov Disord 2003;18:738&#x2013;50. 10.1002/mds.10473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.10473</ArticleId><ArticleId IdType="pubmed">12815652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J. The role of biomarkers in Alzheimer's disease drug development. Adv Exp Med Biol 2019;1118:29&#x2013;61. 10.1007/978-3-030-05542-4_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-05542-4_2</ArticleId><ArticleId IdType="pmc">PMC6750734</ArticleId><ArticleId IdType="pubmed">30747416</ArticleId></ArticleIdList></Reference><Reference><Citation>Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: a review. Autoimmun Rev 2020;19:102512. 10.1016/j.autrev.2020.102512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102512</ArticleId><ArticleId IdType="pubmed">32173519</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, et al. . A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135:847&#x2013;52. 10.1093/brain/awr351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, et al. . Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:279&#x2013;84. 10.3109/21678421.2014.897357</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, et al. . Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2015;86:38&#x2013;44. 10.1136/jnnp-2013-306589</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van Eijk RPA, van den Berg LH. Evidence for a multimodal effect of riluzole in patients with ALS? J Neurol Neurosurg Psychiatry 2019;90:1183&#x2013;4. 10.1136/jnnp-2018-320211</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320211</ArticleId><ArticleId IdType="pubmed">30846539</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey J-H, et al. . Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 2018;17:416&#x2013;22. 10.1016/S1474-4422(18)30054-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsubishi Tanabe Pharma Radicava&#xae; (edaravone injection) [package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation, 2018.</Citation></Reference><Reference><Citation>Sanofi-Aventis U.S. LLC Rilutek&#xae; (riluzole) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2012.</Citation></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505&#x2013;12. 10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone (MCI-186) ALS 19 Study Group Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:55&#x2013;63. 10.1080/21678421.2017.1364269</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1364269</ArticleId><ArticleId IdType="pubmed">28872920</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Stahl DR, et al. . Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:227&#x2013;32. 10.1080/21678421.2016.1265565</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1265565</ArticleId><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Jivraj N, Balendra R, et al. . Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:285&#x2013;91. 10.3109/21678421.2013.872149</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.872149</ArticleId><ArticleId IdType="pubmed">24641613</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, An JW, Oh S-I, et al. . Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:202&#x2013;8. 10.3109/21678421.2014.999791</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.999791</ArticleId><ArticleId IdType="pubmed">25646865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bella ED, Tramacere I, Antonini G, et al. . Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (promise trial). BMJ Open 2017;7:e015434. 10.1136/bmjopen-2016-015434</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-015434</ArticleId><ArticleId IdType="pmc">PMC5724081</ArticleId><ArticleId IdType="pubmed">28801400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>